iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

After inspection, the USFDA issues one observation to the Gland Pharma facility in Hyderabad

28 Aug 2023 , 02:16 PM

On Tuesday, Gland Pharma announced that the US health authorities had inspected its plant in Hyderabad and had issued a Form 483 with one observation. Pre-approval inspections (PAI) for seven products and good manufacturing practice (GMP) inspections were carried out at the business’s Pashamylaram facility in Hyderabad between June 15 and June 27, 2023, the pharmaceutical company reported in a regulatory filing.

One 483 observations were made overall, it continued.

According to Gland Pharma, ‘This observation is of a procedural nature, and corrective and preventive actions for this observation will be submitted to the USFDA within the specified period.’

It was further stated that the observation made was neither new nor connected to data integrity.

The US Food and Drug Administration (USFDA) states that when an inspector finds any situations that could be considered breaches of the Food, Drug, and Cosmetic (FD&C) Act and associated Acts, a Form 483 is given to the management of the company.

For feedback and suggestions, write to us at editorial@iifl.com

Gland Pharma Limited receives EIR from USFDA for Dundigal Facility |  EquityBulls

Related Tags

  • Gland Pharma
  • Hyderabad
  • USFDA
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.